Full history for every metric is available with a Kvantra account
Key financial summary
Financials in HUF| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | HUF bn | 567 | 631 | 803 | 805 | 858 | 863 | 921 | 951 |
| Operating profit | HUF bn | 301 | 310 | ||||||
| Net profit | HUF bn | 105 | 140 | 169 | 159 | 239 | 216 | 229 | - |
| EPS reported | HUF | 1,179 | 1,253 | ||||||
| Operating cashflow per share | HUF | 1,485 | 1,653 | ||||||
| Capex per share | HUF | 216.3 | 222.7 | ||||||
| FCF per share | HUF | 1,269 | 1,430 | ||||||
| Free cash flow | HUF bn | 232 | 255 | ||||||
| Net debt | HUF bn | -257 | -284 | ||||||
| Book value equity | HUF bn | 1,401 | 1,359 | ||||||
| Book value per share | HUF | 7,662 | 7,453 | ||||||
| Number of shares | m | 182.8 | 182.39 | ||||||
| DPS (TTM paid) | HUF | 646.8 | 646.8 |
Financial summary
Financials in HUF| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 6.94 | 6.62 | ||||||
| P/B LTM | x | 1.06 | 1.09 | ||||||
| P/S LTM | x | 1.72 | 1.61 | ||||||
| P/FCF LTM | x | 6.41 | 5.83 | ||||||
| EV/EBITDA LTM | x | 3.63 | 3.67 | ||||||
| EV/Sales LTM | x | 1.50 | 1.31 | ||||||
| Earnings Yield LTM | % | 14.41% | 15.11% | ||||||
| FCF Yield | % | 15.59% | 17.14% | ||||||
| Quality | |||||||||
| ROE | % | 15.40% | 16.73% | ||||||
| ROIC | % | 16.20% | 16.00% | ||||||
| Operating margin | % | 34.85% | 33.69% | ||||||
| Gross margin | % | 68.99% | 67.55% | ||||||
| FCF/Sales | % | 26.88% | 28.19% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -9.82% | -4.16% | ||||||
| Sales Growth YoY | % | +0.59% | +4.83% | ||||||
| Net Income Growth YoY | % | -9.83% | -4.40% | ||||||
| FCF Growth | % | +7.54% | +9.37% | ||||||
| Operating Profit Growth | % | +15.10% | +16.83% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 5.81% | 8.08% | ||||||
| Dividend Growth | % | +24.21% | +24.21% | ||||||
| Payout Ratio | % | 40.11% | 42.78% | ||||||
| FCF/Debt | x | 10.95 | 13.26 | ||||||
| Net Debt/EBITDA | x | -0.54 | -0.69 | ||||||
| EBIT/Net interest | x | 4.10 | 5.81 | ||||||
| Net debt/market cap | % | -17.30% | -19.07% | ||||||
| Net debt/Equity | x | -0.18 | -0.21 | ||||||
| Gross debt/equity | x | 0.02 | 0.01 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Gedeon Richter Plc is a company focused on the development and manufacturing of pharmaceutical products. Its operations are organized into three primary divisions: Pharmaceuticals, Wholesale & Retail, and Other. The Pharmaceutical segment covers all aspects from the research and development of new drugs and their production, through to their sales and marketing. The Wholesale & Retail division is responsible for distributing the company's products to consumers via its network of affiliated companies and pharmacies across various regional markets. The Other segment includes services provided by group members that support marketing and sales activities. The company was established in 1901 by Gedeon Richter and is headquartered in Budapest, Hungary.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Gedeon Richter Plc is a company focused on the development and manufacturing of pharmaceutical products. Its operations are organized into three primary divisions: Pharmaceuticals, Wholesale & Retail, and Other. The Pharmaceutical segment covers all aspects from the research and development of new drugs and their production, through to their sales and marketing. The Wholesale & Retail division is responsible for distributing the company's products to consumers via its network of affiliated companies and pharmacies across various regional markets. The Other segment includes services provided by group members that support marketing and sales activities. The company was established in 1901 by Gedeon Richter and is headquartered in Budapest, Hungary.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free